Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 17.98%.

  • Exagen's EBITDA Margin rose 193100.0% to 17.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.62%, marking a year-over-year increase of 80000.0%. This contributed to the annual value of 24.51% for FY2024, which is 189500.0% up from last year.
  • Exagen's EBITDA Margin amounted to 17.98% in Q3 2025, which was up 193100.0% from 15.29% recorded in Q2 2025.
  • In the past 5 years, Exagen's EBITDA Margin ranged from a high of 15.29% in Q2 2025 and a low of 184.91% during Q2 2022
  • For the 5-year period, Exagen's EBITDA Margin averaged around 51.45%, with its median value being 37.78% (2023).
  • Per our database at Business Quant, Exagen's EBITDA Margin plummeted by -1399500bps in 2022 and then soared by 1501400bps in 2023.
  • Over the past 5 years, Exagen's EBITDA Margin (Quarter) stood at 49.29% in 2021, then tumbled by -129bps to 112.88% in 2022, then surged by 67bps to 37.39% in 2023, then surged by 34bps to 24.77% in 2024, then rose by 27bps to 17.98% in 2025.
  • Its EBITDA Margin stands at 17.98% for Q3 2025, versus 15.29% for Q2 2025 and 21.71% for Q1 2025.